This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $81.21, moving -0.16% from the previous trading session.
Bristol (BMY) Label Expansion of Reblozyl Delayed by 3 Months
by Zacks Equity Research
Bristol Myers (BMY) application seeking label expansion of Reblozy extended by three months by the FDA.
FDA Revises EUA of Glaxo (GSK) & Vir's (VIR) COVID Therapy
by Zacks Equity Research
The FDA restricts the use of sotrovimab, Glaxo (GSK)/Vir's (VIR) COVID therapy, in several states and territories based on the latest data that does not support the therapy's effectiveness against a dominating Omicron subvariant.
AstraZeneca's (AZN) Imfinzi Misses Goal in Cervical Cancer Study
by Zacks Equity Research
AstraZeneca's (AZN) blockbuster drug Imfinzi fails to achieve progression-free survival endpoint with statistical significance in cervical cancer patients during a late-stage study.
Bristol Myers (BMY) Gains 16% YTD: Will the Momentum Continue?
by Zacks Equity Research
Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue.
The Zacks Analyst Blog Highlights Novartis, Merck and Pfizer
by Zacks Equity Research
Novartis, Merck and Pfizer have been included in this Analyst Blog.
Pharma Stock Roundup: NVS, MRK Get FDA Nod, PFE Ulcerative Colitis Study Succeeds
by Kinjel Shah
FDA approves Novartis' (NVS) Pluvicto for a certain type of advanced prostate cancer and Merck's (MRK) Keytruda for expanded use in endometrial carcinoma. Pfizer's (PFE) late-stage ulcerative colitis study on etrasimod meets goal.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Merck (MRK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $79.30 in the latest trading session, marking a +0.3% move from the prior day.
Merck (MRK) Keytruda Gets Another FDA Nod in Endometrial Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda gets approval for advanced endometrial carcinoma therapy in certain patients who are not suited for curative surgery or radiation.
Bristol Myers' (BMY) Opdualag Wins FDA Nod for Melanoma
by Zacks Equity Research
Bristol Myers (BMY) gets FDA approval for a fixed-dose combination of Opdivo (nivolumab) and relatlimab to treat patients 12 years of age or older with unresectable or metastatic melanoma.
AstraZeneca, Merck's Lynparza Cut Risk of Breast Cancer Death
by Zacks Equity Research
Treatment with AstraZeneca (AZN) and Merck's (MRK) Lynparza show meaningful improvement in overall survival for patients with BRCA-mutated HER2-negative high-risk early breast cancer.
Adagene (ADAG) Gets FDA Nod for Cancer Study on ADG126 Combo
by Zacks Equity Research
The FDA grants clearance to Adagene (ADAG) to begin clinical studies on its anti-CTLA-4 mAb, ADG126 in combination with pembrolizumab to treat advanced/metastatic solid tumors.
Here's Why Merck (MRK) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Moderna (MRNA) Up More Than 30% in 10 Days: What Lies Ahead?
by Zacks Equity Research
Moderna's (MRNA) shares are rising presumably in anticipation of rising demand for its COVID-19 vaccine amid authorization for younger population and the fear of another global infection wave.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $78.12, moving -0.66% from the previous trading session.
Iovance (IOVA) to Start Clinical Studies for TIL Therapy
by Zacks Equity Research
Iovance (IOVA) gets FDA nod to start clinical study for IOV-4001, which utilizes the technology licensed from Cellectis. A clinical study in melanoma or NSCLC indication is expected to begin in 2022.
AbbVie (ABBV) Inks Deal to Develop COVID Antiviral Treatment
by Zacks Equity Research
AbbVie (ABBV) joins Scripps Research in the latter's SARS-CoV-2 research program to accelerate the development of new antiviral therapies for COVID-19.
Merck (MRK) Stops Keytruda-Lynparza Combo Prostate Cancer Study
by Zacks Equity Research
Merck (MRK) decides to discontinue a late-stage prostate cancer study evaluating Keytruda in combination with AstraZeneca's Lynparza, following its failure to demonstrate a benefit in overall survival.
Nektar (NKTR) Plunges on Bempeg's Melanoma Study Failure
by Zacks Equity Research
Nektar (NKTR) and Bristol-Myers announce that the bempeg plus Opdivo regimen fails to meet the primary endpoint of progression-free survival and objective response rate in a late-stage melanoma study.
AstraZeneca, Merck's Lynparza Gets FDA Nod for Expanded Use
by Zacks Equity Research
FDA approves AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.
Do Options Traders Know Something About Merck (MRK) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Merck (MRK) stock based on the movements in the options market lately.
Mirati (MRTX) Focuses on Seeking Nod for KRAS Drug Adagrasib
by Zacks Equity Research
Mirati's (MRTX) regulatory filing to the FDA for adagrasib in second-line NSCLC gets a longer-than-expected review period. MRTX is progressing well with the pipeline development for other candidates.